New insider activity at Stryker ( (SYK) ) has taken place on November 20, 2025.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
VP & CFO Preston Wendell Wells recently sold 165 shares of Stryker stock, amounting to a total transaction value of $60,370.
Recent Updates on SYK stock
Stryker Corp’s recent Q3 earnings call highlighted strong business performance with a 9.5% organic sales growth and an 11.1% increase in adjusted earnings per share, driven by high demand across its MedSurg, Neurotechnology, and Orthopedics segments. The company completed strategic acquisitions and achieved record Mako installations, reinforcing its market leadership. However, challenges such as tariffs, which could have a $200 million impact by 2025, and supply chain disruptions were noted. Despite these, Stryker raised its full-year guidance, expecting organic net sales growth between 9.8% to 10.2% and adjusted EPS in the range of $13.50 to $13.60. Analysts adjusted their price targets for Stryker, reflecting the company’s robust performance and strategic initiatives, while also considering external pressures like tariffs and interest expenses.
Spark’s Take on SYK Stock
According to Spark, TipRanks’ AI Analyst, SYK is a Outperform.
Stryker’s overall stock score is driven by strong financial performance and positive earnings call outcomes, reflecting robust growth and strategic execution. However, technical analysis indicates bearish trends, and the high P/E ratio suggests a premium valuation. Despite these challenges, the company’s solid fundamentals and raised guidance support a positive outlook.
To see Spark’s full report on SYK stock, click here.
More about Stryker
YTD Price Performance: 1.84%
Average Trading Volume: 1,472,728
Technical Sentiment Signal: Hold
Current Market Cap: $139.3B